Revenue segments as reported by the company.

Sensor and other revenue

Hardware revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Collaborative research and development fee

Selling, general and administrative

Amortization of intangible assets

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

DexCom

DexCom, Inc. is a medical device manufacturing company, which engages in the design, development and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6 CGM System, DexCom G6 CGM System for Medicare, Software and Mobile apps. The company was founded by John F. Burd on May 1, 1999 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

DexCom excels in Q4 2022, eyes international expansion and margin growth

DexCom's Q4 2022 showcased robust financials, operational efficiency, and strategic advancements. The company is well-positioned for continued growth in 2023, with a focus on international expansion, marketing investments, and margin optimization.

DexCom excels in Q1, eyes international growth and market expansion

DexCom's strong Q1 performance and strategic initiatives position the company for sustained growth.
Balancing cost management, market expansion, and product enhancements will be crucial for future success.
Opportunities in new markets, user segments, and product improvements offer avenues for continued growth.
Overall, DexCom's focus on innovation and customer-centric strategies bode well for its long-term prospects.

DexCom reports robust Q2 earnings, eyes international expansion and new products

DexCom's Q2 performance reflects strong revenue growth and market momentum, supported by successful product launches and international expansion.
The company's focus on innovation, customer satisfaction, and cost reduction initiatives positions it well for continued success and market leadership.
While facing challenges in customer experience and product adoption, DexCom's strategic strengths and growth opportunities signal a promising outlook for the future.

DexCom achieves record Q3 performance and expands market leadership

DexCom's Q3 performance reflects strong revenue growth, operational efficiency, and strategic market expansion efforts, setting new records in financial metrics.
The company's strengths lie in market leadership, product innovation, and proactive market expansion strategies, supported by a strong brand and organizational culture.
While facing challenges in pricing strategies, timeline for revenue contributions, and distribution accessibility, DexCom is well-positioned to capitalize on opportunities in new markets and product launches.
Overall, DexCom's performance, strengths, and proactive approach to challenges and opportunities position it for sustained growth and market leadership in the medical devices sector.

DexCom excels in Q4 2023, eyes growth through strategic initiatives

DexCom's strong financial performance, product launches, and market expansions in 2023 set a solid foundation for future growth.
Strategic investments, competitive advantages, and a focus on margin progression position DexCom for continued success.
Challenges in reimbursement pathways and market penetration are being addressed, while opportunities in expanding coverage and product enhancements are being pursued.

DexCom excels in Q1 2024, eyes global expansion and innovation

DexCom's strong financial performance, strategic market expansions, and product innovations position the company for continued growth and success.
While facing challenges in market penetration and product adoption timelines, DexCom's focus on user experience and healthcare outcomes remains a key strength.
Opportunities lie in international market expansion, product differentiation, and leveraging sensor technology for improved patient care and business growth.

DexCom reports 15% revenue growth but lowers full-year guidance

DexCom faced challenges in customer additions and revenue per customer in the U.S. and below-expectation international performance. Despite this, they reported 15% revenue growth and lowered full-year revenue guidance to 11%-13% organic growth.

DexCom meets revenue targets, Stelo launch successful, challenges ahead

DexCom's Q3 performance met expectations with growth in key areas.
Strong market reception for Stelo presents revenue and growth opportunities.
Challenges exist in managing differing customer expectations and sensor performance.
Opportunities lie in expanding international markets and enhancing customer experiences.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6, Dexcom G7, Dexcom Stelo, Dexcom Share, Dexcom Real-Time API, and Dexcom ONE. The company was founded by John F. Burd on May 13, 1999 and is headquartered in San Diego, CA.

The stock price of Dexcom, best known for its continuous glucose monitoring systems, has seen a drop of 8% over the last month, while it was down 5% on Friday, Feb 11, due to the company's downbeat Q4 results. Dexcom's revenue of $698.5 million was slightly above the consensus estimate.

Should You Buy Dexcom Stock After Its Downbeat Q4?

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on the company at the following upcoming virtual investor conferences: Brice Bobzien, Vice President, Finance will present on behalf of the company at the SVB Leerink 11th Annual Global Healthcare Conference on Wednesday, February 16, 2022 at 5:00pm (EST). Jereme Sylvain, Executive Vice President and Chief Financial Officer will present on behalf of the company at the Citi 2022 Healthca

Dexcom Announces Upcoming Virtual Conference Presentations

DexCom's (DXCM) fourth-quarter results benefit from domestic and international revenue growth and solid new customer additions.

DexCom (DXCM) Q4 Earnings Miss, Revenues Beat Estimates

Dexcom, Inc. (DXCM) CEO Kevin Sayer on Q4 2021 Results - Earnings Call Transcript

DexCom (DXCM) delivered earnings and revenue surprises of -20.93% and 0.03%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

DexCom (DXCM) Q4 Earnings Lag Estimates

SAN DIEGO--(BUSINESS WIRE)---- $DXCM #CGM--Dexcom Reports Fourth Quarter and Fiscal Year 2021 Financial Results

Dexcom Reports Fourth Quarter and Fiscal Year 2021 Financial Results

Amgen

Starbucks

Zoom Video

Airbnb

Illumina

JD.com

Lucid Group

Tech stocks got off to a positive start Wednesday morning. The Nasdaq traded up about 1.3%, the S&P 500 was up 1.04% and the Dow traded 0.7% higher shortly after the opening bell.

Wednesday Morning's 14 Tech Stock Movers Include Amgen, Starbucks and Zoom

BURNABY, British Columbia--(BUSINESS WIRE)---- $DXCM #cgm--The Dexcom G6 Continuous Glucose Monitoring (CGM) System is now covered in Alberta for children and youth living with diabetes.

Dexcom G6 Continuous Glucose Monitoring System Now Covered in Alberta for Children and Youth Living With Diabetes

DexCom (DXCM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: DexCom (DXCM) Q4 Earnings Expected to Decline

DexCom One and G7 can prove to be a solid growth catalysts for this leading CGM player. DexCom has also secured FDA approval for two key software solutions, which can further help the company integrate its data more effectively with connected electronic devices and third-party health apps.

DexCom: Buy The Dip For Robust Product Portfolio And Healthy Financials

SAN DIEGO--(BUSINESS WIRE)---- $DXCM #DXCM--Dexcom Schedules Fourth Quarter and Full Year 2021 Earnings Release and Conference Call for February 10, 2022 at 4:30 p.m. Eastern Time

Dexcom Schedules Fourth Quarter and Full Year 2021 Earnings Release and Conference Call for February 10, 2022 at 4:30 p.m. Eastern Time.

DexCom (DXCM) posts solid fourth-quarter and full-year 2021 revenue data on the back of resilience shown in the face of the COVID-19 induced challenges.

DexCom (DXCM) Posts Solid Preliminary Q4 and 2021 Revenues

SAN DIEGO--(BUSINESS WIRE)---- $dxcm #CGM--Dexcom Reports Preliminary, Unaudited Revenue for the Fourth Quarter 2021 and Summary Data from the Dexcom G7 U.S. Pivotal Trial

Dexcom Reports Preliminary, Unaudited Revenue for the Fourth Quarter 2021 and Summary Data from the Dexcom G7 U.S. Pivotal Trial

SAN DIEGO--(BUSINESS WIRE)--Dexcom to Present at 40th Annual J.P. Morgan Healthcare Conference

Dexcom to Present at 40th Annual J.P. Morgan Healthcare Conference

Boston Scientific

Medtronic

Syneos Health

Stocks like Boston Scientific (BSX), Medtronic (MDT), DexCom (DXCM) and Syneos Health (SYNH) are evolving rapidly in the field of IoMT.

4 Internet of Medical Things (IoMT) Stocks to Buy for 2022

DexCom is one of the leaders in the diabetes care space with their continuous glucose monitoring device. Advanced technology and convenience of use have propelled their revenue growth upward over the past several years.

DexCom: Fast Growing Medical Device Company For Diabetes Care

Investors continue to be optimistic about DexCom (DXCM) owing to its strong product portfolio.

Here's Why You Should Retain DexCom (DXCM) Stock For Now

This is one of the fastest-growing healthcare stocks right now.

Here's Why Investors Should Consider DexCom Stock

CNH Industrial NV

Zebra Technologies

Zoetis

When a company's return on equity (ROE) ratio is better than most of its competitors, it generally indicates that the company has been very efficient in generating profits. Thus, investors may want to consider the following stocks, as they are performing better than most of their peer group companies in terms of a higher ROE ratio.

4 Large-Cap Stocks With High Returns on Equity

This healthcare company isn't done beating the market.

3 Reasons This Stock Could 10X in 10 Years

Abbott Labs

Abbott's the heavyweight, and DexCom is the formidable challenger.

Better Buy: DexCom or Abbott Labs?

Intuitive Surgical

Novavax

Ocugen, Inc.

Are these the top picks in the health care industry right now?

4 Top Health Care Stocks For Your November 2021 Watchlist

DexCom (DXCM) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Earnings Estimates Rising for DexCom (DXCM): Will It Gain?

The stock price of Dexcom, best known for its continuous glucose monitoring systems, has seen a rise of 10% last week, while it is up 14% in a month. The recent rise can be attributed to upbeat Q3 results.

What's Happening With Dexcom Stock?

SAN DIEGO--(BUSINESS WIRE)---- $DXCM #CGM--DEXCOM, NICK JONAS, PATTI LABELLE AND THE GLOBAL MOVEMENT FOR TIME IN RANGE INVITE THE WORLD TO #SEEDIABETES THIS NOVEMBER

News for DexCom Stock (DXCM)